Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- 26 Japan Drug Makers’ Annual Pay Averages 8.21 Million Yen, 5 Firms Top 10 Million Yen Mark
July 7, 2021
- Keytruda Retains Top Spot in Japan Drug Ranking in June: Encise
July 7, 2021
- Sosei Teams Up with InveniAI on GPCR-Targeted Drug Discovery
July 7, 2021
- Astellas Revamping Sales Organization as Product Mix Shifts towards Specialty Area: CEO
July 6, 2021
- CEO Says Astellas Pivoting to Specialty Drugs, Going Global: Full Interview
July 6, 2021
- Sagent Jettisons Camostat Mesilate for COVID-19 after PII Miss: Nichi-Iko
July 6, 2021
- Reps’ Face-to-Face Meetings Up 76.1% YOY in May: Intage
July 6, 2021
- All Ranitidine Tablet Drugs to Be Discontinued in Japan over Carcinogen Woes
July 5, 2021
- Astellas Begins COVID-19 Vaccination Program
July 5, 2021
- Ivermectin to Enter 1st Company-Sponsored COVID-19 Trial in Japan
July 2, 2021
- 3 Major Wholesalers, 7 Employees Found Guilty in Bid-Rigging Trial
July 2, 2021
- Ayumi to Leverage IT to Boost Sales and Marketing, Eyes More Licensing Deals
July 2, 2021
- Towa Now Curbs Shipments for 235 Products; 27 Added to Restriction List
July 2, 2021
- Kaken Grants European Rights for Efinaconazole to Almirall
July 2, 2021
- Mitsubishi Tanabe Rolls Out Oral Film ALS Drug in US
July 2, 2021
- Ex-BMS Exec Tsuji Takes Reins of Mundipharma Japan
July 2, 2021
- Solasia Files NDA for PTCL Drug in Japan
July 2, 2021
- Shionogi’s Chinese JV Commences RWD Collection, Analysis of Metabolic Diseases
July 2, 2021
- Takeda Revises Rules to Enable Fully Virtual Shareholders Meetings
July 1, 2021
- Nichi-Iko Expects Shipment Controls to Linger beyond April Next Year for 110 Products
July 1, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…